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in lifetime costs and utilities of $17,208 and 10.4124 QALYs compared with $16,780
and 10.4057 QALYs for prasugrel therapy. The ICER for clopidogrel was $63,840/
QALYs. The acceptability curve showed that prasugrel was not likely cost-effective
with 80% certainty at any WTP threshold. One-way sensitivity analyses (WTP
decision threshold: $100,000/QALY) showed that prasugrel is the most cost-effec-
tive strategy when probability of MI is increased by12%, probability of bleeding is
decreased by 24%, and disutility associated with MI is 0.1634. When only pa-
tients with variant CYP2C19 were considered, the ICER was found to be $2,313,333/
QALY for clopidogrel. CONCLUSIONS: Inconclusive results indicate that there is no
benefit in prescribing one therapy over the other for the entire patient population.
CYP2C19 polymorphism should be given consideration during the decisionmaking
process. For the base-case scenario, prasugrel therapywas the preferred strategy in
patients with variant CYP2C19.
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OBJECTIVES: To evaluate the cost-effectiveness of rivaroxaban compared with
dabigatran and enoxaparin for the prophylaxis of venous thromboembolism in
patients undergoing elective total hip replacement (THR) in the context of Russian
health care system.METHODS: A decision-tree model on the choice of regimens
for thromboprophylaxis after THR was adopted from the model, developed by
McCullagh et. al. (2009). Primary outcomes was mortality, occurrence of distal and
proximal DVT, rates of symptomatic PE. Incidence of gastrointestinal bleeding,
stroke and death was also included into the model. Delphi method was used to
determine typical practice and cost ofmanagement of DVT and PE. It was assumed
that patients with DVTwere treated for 90 days, patients with PE – for 180 days. All
patients in the model received thromboprophylaxis with one of the following reg-
imens: rivaroxaban dose of 10 mg/day orally for 31-39 days (RECORD 2); dabigatran
dose of 220 mg/day orally for 28-35 days (RE-NOVETE); enoxaparin dose of 40 mg/
day subcutaneously for 10-14 days (RECORD 2). Incremental cost-effectiveness ra-
tios (ICERs) were calculated. RESULTS: The cost of prophylaxis with enoxaparin
was 6991 USD, with dabigatran - 7076 USD, with rivaroxaban - 7147 USD. Although
rivaroxaban has more effectiveness in preventing DVT (0.016 vs. 0.082 vs. 0.045)
and PE (0.0012 vs. 0.005 vs. 0.004) than enoxaparin and dabigatran correspondingly.
ICER to prevent 1 case of deep vein thrombosis after THR in rivaroxaban versus
enoxaparin was 23.6 USD, and in dabigatran versus enoxaparin was 22.9 USD. ICER
to prevent 1 case of pulmonary thromboembolism after THR in rivaroxaban versus
enoxaparin was 556.7 USD, and in dabigatran versus enoxaparin was 850.3 USD.
CONCLUSIONS: Despite of higher cost of prophylaxis of DVT and PE with rivaroxa-
ban, comparing to enoxaparin and dabigatran, prophylaxis with rivaroxaban was
more effective with acceptable ICERs.
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OBJECTIVES: New medicines are launched based on a limited number of clinical
trials. Payers, providers, and patients base their utilization decisions on this infor-
mation. Furthermore, projected cost-effectiveness and real world cost-effective-
ness are moving targets that may differ greatly, especially early in the product life
cycle.We examine this divergence using clopidogrel, an antiplateletmedication for
preventing strokes and heart attacks, as a case study. METHODS: Using the Na-
tional Ambulatory Medical Care Survey (NAMCS) data from 1998 to 2008, we esti-
mate changes in the volume and distribution of patient prescriptions by age,
gender, and race. We combine these time trends with estimates from the
pharmacoeconomics literature on cost-effectivenessmeasured as cost per quality-
adjusted life year (QALYs). RESULTS: From 1998 (following approval in November
1997) to 2001, the average age of clopidogrel patients dropped from 77 to 70. Over
the same period, the percentage of patients who were under 54 years of age in-
creased from 0% to 13%. Comparing the real-world patient population to a pivotal
phase 3 trial also reveals a large difference in gender mix: 72% male in the trial vs.
45% in NAMCS in 1998. Similar trends were found for race: by 2008, patients were
much less likely to be white than in the trial—only 82% versus 95%. In 1999, 1.7
million office visits included a prescription for clopidogrel, 7.5 times as many as in
1998. By 2008, almost 16million prescriptionswerewritten—1.5 for every 100 office
visits. Adjusting for demographic mix, the estimated real-world CE improved be-
tween 2000 and 2001 by 16% ($25,000 per QALY vs. $21,000, respectively). From 1998
to 2008, the CE ratio fell by 23%. CONCLUSIONS: These results demonstrate that
cost-effectiveness projected at launch may provide only limited indication of the ul-
timate real-world impact, which improved substantially over time, in this example.
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OBJECTIVES: To evaluate and compared the long-term costs and outcomes of four
warfarin treatment strategies of CYP2C9, VKORC1, both CYP2C9 and VKORC1 gen-
otype-guided dosing, and standard warfarin dosing among nonvalvular VTE pa-
tients in the societal perspective. METHODS: A discrete event simulation model
was used to depict patients’ health states as the disease evolves with time, and
captured its associated costs (2007 U.S. dollars) and quality of life. Data was extrap-
olated with the criteria of including VTE patients of age 18 years on warfarin
with INR target of 2-3. Probabilities, costs and humanistic properties were obtained
from the literature, HCUP (NIS & SEDD), and the Medicare Reimbursement Sched-
ule databases. Sensitivity analysis was performed for uncertainty parameters in
the model. All costs and benefits were discounted at 3%. RESULTS: There was a
significant difference in the prevalence of bleeding complication between standard
anticoagulation (6.1%) and the genotype –guided of CYP2C9 and VKORC1 groups
(5.8%). The mean cost and QALYs per patients were $14,340 and 8.1251. The
genotype-guided warfarin anticoagulation strategies projected higher cost and
higher QALYs. However, considering the threshold of $100,000/QALY, VKORC1 gen-
otype-guided was indicated to be cost-effective among all strategies. Sensitivity
analysis demonstrated 25% of the replications of both CYP2C9 and VKORC1 geno-
type-guided strategy to be $100,000/QALY. CONCLUSIONS: This study showed
that testing for multiple genotypes of CYP2C9 and VKORC1 to guide warfarin anti-
coagulation therapy is not cost –effective in all population and that patient with
higher risk of complications are more likely to benefit from this new innovation.
For the genotype-guided test to be cost-effective in the population with VTE, the
cost of the test would have to be $400 or be restricted to patient at high risk for
bleeding complications (RR5.8).
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OBJECTIVES: The PLATO trial showed that in patients with acute coronary syn-
dromes (ACS) treatment with ticagrelor compared with clopidogrel significantly
reduced the rate of myocardial infarction (MI), stroke, or death from vascular
causeswithout a significant increase in the rate of overallmajor bleeding. Based on
clinical and health-economic data from PLATO the present study evaluates the
long-term cost-effectiveness of treating patients with ticagrelor based on the EU
label.METHODS: A two-part decision-analytic model, comprising a one-year deci-
sion tree and a long-termMarkovmodel, was constructed to estimate lifetime costs
and QALYs of treating ACS patients for one year with ticagrelor plus acetylsalicylic
acid (ASA) comparedwith clopidogrel plus ASA. Using individual-patient data from
PLATO, event rates, health-care costs (Swedish in base-case analysis), and QALYs
were estimated for the first year. For the second year onwards, necessary assump-
tions and external data sources were utilized to extrapolate quality-adjusted sur-
vival conditional onwhether a non-fatalMI, a non-fatal stroke or no event occurred
during the first year. A probabilistic analysis was performed and incremental cost-
effectiveness ratios are presented from a health-care perspective in 2010 prices. A
generic clopidogrel price of €0.17 ($0.23) per day, and a ticagrelor price range of €2.25
($3.00) to €3.50 ($4.65) per day were applied. RESULTS: Treatment with ticagrelor
was associated with a QALY gain of 0.13 compared with clopidogrel. The cost per
QALY gained with ticagrelor was in the range of €2,350 ($3,110) to €5,700 ($7,550)
compared with clopidogrel. Ticagrelor is likely to be cost-saving if proprietary
clopidogrel prices are applied. The results were consistent in major sub groups
across the broad ACS population. CONCLUSIONS: Based on clinical and health-
economic evidence from the PLATO study, treating a broad spectrum of ACS pa-
tients with ticagrelor for one year based on the European label is cost-effective
compared with clopidogrel.
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OBJECTIVES: Associated use of antithrombotics, antiplatelets and invasive strate-
gies in patients with non ST-segment elevation acute coronary syndromes (NSTE-
ACS) reduces cardiovascular events, however, with an increase in the risk of bleed-
ing. Clinical studies showed that fondaparinux is as effective as enoxaparin in
treating patients with NSTE-ACS, but with reduced risk of bleeding events. The
objective was to determine the cost-effectiveness of fondaparinux versus enoxa-
parin in patients with NSTE-ACS in Brazil from the perspective of the Brazilian
Ministry of Health (MoH). METHODS: An analytic decision tree model was con-
ducted to estimate the resultant costs and consequences of the targeted therapies
in patients with NSTE-ACS. Model input data derived from the OASIS-5 study
(N20,078 NSTE-ACS patients randomized to fondaparinux or enoxaparin). The
analyzed outcome was a composite of cardiovascular events (i.e., death, acute
myocardial infarction, stroke, and major bleedings). Model time horizon was 9, 30,
and 180 days post-NSTE-ACS. Direct costs of NSTE-ACS events and treatments
were computed (i.e., drugs, coronary angiography, myocardial revascularization,
percutaneous intervention - PCI, hospitalizations, etc.). Costs were expressed in
2010 Brazilian currency (1BRL0.59USD). Univariate andmultivariate (Monte Carlo)
analyses tested model robustness. RESULTS: At day 9, the average cost per patient
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